Tau positron emission tomography results from TOGETHER, a double‐blind, placebo‐controlled Phase II study of bepranemab in prodromal–mild Alzheimer’s disease
TOGETHER provides the first clinical demonstration of slowing of tau accumulation with an antibody targeting the tau mid-region, as evidenced by tau PET imaging, and marks the first time that any tau-directed therapy has demonstrated a clinical benefit.
Authors
- Bart Van Den Steen
- Jos Bloemers
- Matthew E. Barton
- Ralph Paul Maguire (ORCID: https://orcid.org/0000-0003-3937-6622)
- Steve Einstein
- Katie Taiyari
- Tim Buchanan (ORCID: https://orcid.org/0000-0003-1218-5420)
- William Byrnes
- Irene Rebollo Mesa
- Hans L.G Van Tricht
- Omobola Famodimu
- Colin Ewen
Institutions
- North Carolina State University (US)
- Unidades Centrales Científico-Técnicas (ES)
- Geotab (Canada) (CA)
- UCB Pharma (United Kingdom) (GB)
- UCB Pharma (Netherlands) (NL)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_099279
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00